Aurinia Pharmaceuticals (AUPH) Net Income towards Common Stockholders Growth (5y) (2020 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Aurinia Pharmaceuticals | 2.03 Bn | 1.65 Bn | 71.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21.81% |
| Dec 31, 2025 | 94.87% |
| Sep 30, 2025 | 15.68% |
| Jun 30, 2025 | 15.79% |
| Mar 31, 2025 | 15.78% |
| Dec 31, 2024 | 14.92% |
| Sep 30, 2024 | 16.00% |
| Jun 30, 2024 | 14.93% |
| Mar 31, 2024 | 41.11% |
| Dec 31, 2023 | 26.71% |
| Sep 30, 2023 | 40.21% |
| Jun 30, 2023 | 40.74% |
| Mar 31, 2023 | 32.85% |
| Dec 31, 2022 | 31.22% |
| Sep 30, 2022 | 46.22% |
| Jun 30, 2022 | 29.77% |
| Mar 31, 2022 | 29.73% |
| Dec 31, 2021 | 1.51% |
| Sep 30, 2021 | -1,090.67% |
| Jun 30, 2021 | -1,262.82% |
| Mar 31, 2021 | -1,211.18% |
| Dec 31, 2020 | -809.14% |
| Sep 30, 2020 | -1,841.15% |
| Jun 30, 2020 | -2,558.48% |